Endocrine Requirements for Oocyte Maturation Following hCG, GnRH Agonist, and Kisspeptin During IVF Treatment

Objective The maturation of oocytes to acquire competence for fertilization is critical to the success of in vitro fertilization (IVF) treatment. It requires LH-like exposure, provided by either human chorionic gonadotropin (hCG), or gonadotropin releasing hormone agonist (GnRHa). More recently, the hypothalamic stimulator, kisspeptin, was used to mature oocytes. Herein, we examine the relationship between the endocrine changes following these agents and oocyte maturation. Design Retrospective cohort study. Methods Prospectively collected hormonal data from 499 research IVF cycles triggered with either hCG, GnRHa, or kisspeptin were evaluated. Results HCG-levels (121 iU/L) peaked at 24 h following hCG, whereas LH-levels peaked at ~4 h following GnRHa (140 iU/L), or kisspeptin (41 iU/L). HCG-levels were negatively associated with body-weight, whereas LH rises following GnRHa and kisspeptin were positively predicted by pre-trigger LH values. The odds of achieving the median mature oocyte yield for each trigger were increased by hCG/LH level. Progesterone rise during oocyte maturation occurred precipitously following each trigger and strongly predicted the number of mature oocytes retrieved. Progesterone rise was positively associated with the hCG-level following hCG trigger, but negatively with LH rise following all three triggers. The rise in progesterone per mature oocyte at 12 h was greater following GnRHa than following hCG or kisspeptin triggers. Conclusion The endocrine response during oocyte maturation significantly differed by each trigger. Counter-intuitively, progesterone rise during oocyte maturation was negatively associated with LH rise, even when accounting for the number of mature oocytes retrieved. These data expand our understanding of the endocrine changes during oocyte maturation and inform the design of future precision-triggering protocols.

[1]  C. Andersen,et al.  Shortcomings of an unphysiological triggering of oocyte maturation using human chorionic gonadotropin. , 2020, Fertility and sterility.

[2]  P. Humaidan,et al.  Determinants of the hCG Concentration in the Early Luteal Phase After Final Maturation of Follicles With Bolus Trigger of Recombinant hCG , 2020, Frontiers in Endocrinology.

[3]  Dose Finding Study , 2020, Definitions.

[4]  P. Humaidan,et al.  The early luteal hormonal profile in IVF patients triggered with hCG. , 2020, Human reproduction.

[5]  H. Tournaye,et al.  Predicting suboptimal oocyte yield following GnRH agonist trigger by measuring serum LH at the start of ovarian stimulation. , 2019, Human reproduction.

[6]  W. Dhillo,et al.  Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment , 2018, Endocrine reviews.

[7]  W. Dhillo,et al.  Follicle Size on Day of Trigger Most Likely to Yield a Mature Oocyte , 2018, Front. Endocrinol..

[8]  P. Humaidan,et al.  Daytime Variation in Serum Progesterone During the Mid-Luteal Phase in Women Undergoing In Vitro Fertilization Treatment , 2018, Front. Endocrinol..

[9]  W. Dhillo,et al.  Clinical parameters of ovarian hyperstimulation syndrome following different hormonal triggers of oocyte maturation in IVF treatment , 2018, Clinical endocrinology.

[10]  L. Huson,et al.  A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial , 2017, Human reproduction.

[11]  K. Raghavender,et al.  Effect of kisspeptin on in vitro maturation of sheep oocytes , 2017, Veterinary world.

[12]  L. Priskorn,et al.  Dynamic GnRH and hCG testing: establishment of new diagnostic reference levels. , 2017, European journal of endocrinology.

[13]  Z. Rosenwaks,et al.  Dose of human chorionic gonadotropin to trigger final oocyte maturation , 2016 .

[14]  P. Humaidan,et al.  Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study. , 2016, Fertility and sterility.

[15]  D. Ashby,et al.  Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy , 2015, The Journal of clinical endocrinology and metabolism.

[16]  S. Bloom,et al.  Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men , 2015, Human reproduction.

[17]  P. Humaidan,et al.  Ovarian hyperstimulation syndrome in the 21st century: the role of gonadotropin-releasing hormone agonist trigger and kisspeptin , 2015, Current opinion in obstetrics & gynecology.

[18]  R. Machtinger,et al.  Co-administration of GnRH-agonist and hCG for final oocyte maturation (double trigger) in patients with low number of oocytes retrieved per number of preovulatory follicles-a preliminary report , 2014, Journal of Ovarian Research.

[19]  D. Ashby,et al.  Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. , 2014, The Journal of clinical investigation.

[20]  P. Humaidan,et al.  Pharmaceutical Options for Triggering of Final Oocyte Maturation in ART , 2014, BioMed research international.

[21]  Yulian Zhao,et al.  Worldwide survey of IVF practices: trigger, retrieval and embryo transfer techniques , 2014, Archives of Gynecology and Obstetrics.

[22]  J. Glaser.  Time to reconsider. , 2013, The Journal of bone and joint surgery. American volume.

[23]  N. Santoro,et al.  Evidence of GnRH antagonist escape in obese women. , 2013, The Journal of clinical endocrinology and metabolism.

[24]  M. Simoni,et al.  LH and hCG Action on the Same Receptor Results in Quantitatively and Qualitatively Different Intracellular Signalling , 2012, PloS one.

[25]  Byeong-chun Lee,et al.  Paradoxical effects of kisspeptin: it enhances oocyte in vitro maturation but has an adverse impact on hatched blastocysts during in vitro culture. , 2012, Reproduction, fertility, and development.

[26]  W. Guo,et al.  Circulating luteinizing hormone level after triggering oocyte maturation with GnRH agonist may predict oocyte yield in flexible GnRH antagonist protocol. , 2012, Human reproduction.

[27]  B. Tarlatzis,et al.  GnRHa to trigger final oocyte maturation: a time to reconsider. , 2010, Human reproduction.

[28]  S. Daneshmand,et al.  Comparison of human chorionic gonadotropin and gonadotropin-releasing hormone agonist for final oocyte maturation in oocyte donor cycles. , 2007, Fertility and sterility.

[29]  A. Pellicer,et al.  Expression of KiSS-1 in rat ovary: putative local regulator of ovulation? , 2006, Endocrinology.

[30]  R. Steiner,et al.  Kisspeptin Activation of Gonadotropin Releasing Hormone Neurons and Regulation of KiSS-1 mRNA in the Male Rat , 2005, Neuroendocrinology.

[31]  P. Devroey,et al.  Reproductive biology and IVF: ovarian stimulation and luteal phase consequences , 2003, Trends in Endocrinology & Metabolism.

[32]  J. Marshall,et al.  Hypothalamic regulation of cyclic ovulation: evidence that the increase in gonadotropin-releasing hormone pulse frequency during the follicular phase reflects the gradual loss of the restraining effects of progesterone. , 2002, The Journal of clinical endocrinology and metabolism.

[33]  M. van Wely,et al.  GnRHa to trigger final oocyte maturation: a time to reconsider. , 2010, Human reproduction.

[34]  Ekaterina Voronina,et al.  The regulation of oocyte maturation. , 2003, Current topics in developmental biology.